Walleye Trading
BCRX icon

Walleye Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,777
Closed -$185K – 4142
2025
Q4 		$185K Buy
+23,777
New +$172K ﹤0.01% 3432
2024
Q1 		– Sell
-55,761
Closed -$334K – 4761
2023
Q4 		$334K Buy
55,761
+45,805
+460% +$265K ﹤0.01% 3408
2023
Q3 		$70.5K Buy
9,956
+9,466
+1,932% +$68K ﹤0.01% 4109
2023
Q2 		$3.45K Buy
+490
New +$3.93K ﹤0.01% 4407
2023
Q1 		– Sell
-62,105
Closed -$598K – 4852
2022
Q4 		$713K Buy
62,105
+46,016
+286% +$574K ﹤0.01% 2534
2022
Q3 		$203K Buy
16,089
+4,669
+41% +$60.1K ﹤0.01% 3657
2022
Q2 		$121K Sell
11,420
-7,912
-41% -$81.6K ﹤0.01% 4038
2022
Q1 		$314K Sell
19,332
-17,390
-47% -$279K ﹤0.01% 3404
2021
Q4 		$509K Sell
36,722
-87,981
-71% -$1.16M ﹤0.01% 2946
2021
Q3 		$1.79M Buy
124,703
+21,006
+20% +$331K 0.01% 1703
2021
Q2 		$1.64M Buy
+103,697
New +$1.41M 0.01% 1665
2021
Q1 		– Sell
-18,772
Closed -$140K – 4805
2020
Q4 		$140K Buy
+18,772
New +$96.8K ﹤0.01% 3745
2020
Q2 		– Sell
-42,086
Closed -$84K – 4235
2020
Q1 		$84K Sell
42,086
-3,000
-7% -$8.26K ﹤0.01% 3207
2019
Q4 		$156K Buy
+45,086
New +$113K ﹤0.01% 3332
2018
Q4 		– Sell
-1,245
Closed -$9K – 4627
2018
Q3 		$9K Buy
+1,245
New +$8.36K ﹤0.01% 5002
2017
Q2 		– Sell
-37,700
Closed -$317K – 4490
2017
Q1 		$317K Buy
+37,700
New +$262K ﹤0.01% 2608
2016
Q1 		– Sell
-2,000
Closed -$21K – 5319
2015
Q4 		$21K Sell
2,000
-1,600
-44% -$15.9K ﹤0.01% 4389
2015
Q3 		$41K Buy
3,600
+3,100
+620% +$41.4K ﹤0.01% 3639
2015
Q2 		$7K Buy
+500
New +$5.68K ﹤0.01% 4398

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Walleye Trading's BCRX Position: Q1 2026 in Review

Walleye Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 23,777 shares — an estimated $185K sold.

Walleye Trading first reported a position in BCRX in Q2 2015 and held it in 19 quarters. The position peaked at $1.79M in Q3 2021. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Walleye Trading reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 23,777 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $185K.
  • Walleye Trading first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Walleye Trading's BioCryst Pharmaceuticals position peaked at $1.79M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.